title: Effects of recombinant human erythropoietin on haemolytic anaemia in mice.
abstract: The effects of repeated administration of recombinant human erythropoietin (rHuEPO) were investigated in mice with haemolytic anaemia. Mice with haemolytic anaemia induced by phenylhydrazine (PHZ mice) were examined as an acute model and New Zealand black mice (NZB mice) at 13 months of age were examined as a chronic model. The plasma erythropoietin (EPO) level in PHZ mice was high and showed a strong inverse correlation with the Hb in the anaemia development period. However, it was relatively low in the recovery period from anaemia. On the other hand, the plasma EPO level in NZB mice showed a simple inverse correlation with the Hb. The rHuEPO was injected every day for a week into these mice. While a high plasma EPO level was maintained in PHZ mice, no significant effect was observed by injection with rHuEPO at dose of 600 IU/kg. However, in the recovery period from anaemia, RBC and haemoglobin in PHZ mice were increased by the rHuEPO treatment and recovered more quickly to their normal levels. In NZB mice, RBC and haemoglobin were also increased by treatment with rHuEPO at dose of 600 IU/kg. Anti-RBC autoantibodies and anti-EPO antibodies did not increase, while RBC and plasma EPO levels were increased by the rHuEPO treatment. These results suggest that some types of haemolytic anaemia are not always combined with high endogenous EPO levels and that exogenous rHuEPO may be effective for use in the treatment of haemolytic anaemia.
authors: Fujigotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan.
authors: O
authors: O
authors: Cynshi
authors: Y
authors: Y
authors: Shimonaka
authors: M
authors: M
authors: Higuchi
authors: N
authors: N
authors: Imai
authors: H
authors: H
authors: Suzuki
authors: M
authors: M
authors: Togashi
authors: M T
authors: MT
authors: Okamoto
authors: K
authors: K
authors: Hirashima
mesh_terms: D000208:Acute Disease; D000743:Anemia, Hemolytic / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D000818:Animals; D000906:Antibodies / Q000032:analysis; D001789:Blood Group Antigens / Q000276:immunology; D002908:Chronic Disease; D004921:Erythropoietin / Q000097:blood / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D008297:Male; D051379:Mice; D008814:Mice, Inbred NZB; D010659:Phenylhydrazines; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000906:Antibodies; D001789:Blood Group Antigens; D006454:Hemoglobins; D010659:Phenylhydrazines; D011994:Recombinant Proteins; D004921:Erythropoietin